This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    News
    12/11/24

    Aldeyra announces first patient enrolled in the phase III TRANQUILITY trial of reproxalap for the treatment of dry eye disease.

    Aldeyra Therapeutics, Inc. announced enrollment of the first patient in the Phase III TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/06/22

    Primary endpoint in phase III TRANQUILITY-2 trial in dry eye disease is achieved and plans are to submit a NDA for symptoms and three sign endpoints of dry eye disease.

    Aldeyra Therapeutics, Inc. announced the achievement of the primary endpoint in the Phase III TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Aldeyra Therapeutics announces top-line results from the phase III TRANQUILITY trial of 0.25% reproxalap in dry eye disease.

    Aldeyra Therapeutics, Inc. announced top-line results from the Phase III TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/04/23

    Results from Phase III ESSENCE-2 trial for CyclASol in dry eye disease published in JAMA Ophthalmol

    Novaliq announced that results from the second pivotal Phase III ESSENCE-2 trial for CyclASol (cyclosporine 0.05 in SFA) have been published in Journal of the American Medical Association (JAMA) Ophthalmology

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/10/22

    CyclASol filed with FDA and accepted for dry eye disease

    Novaliq announced that the FDA has accepted the New Drug Application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    04/10/24

    Aldeyra Therapeutics resubmits reproxalap new drug application to FDA for the treatment of dry eye disease

    Aldeyra Therapeutics, Inc. announced the resubmission of a New Drug Application (NDA) to the FDA for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/06/23

    FDA approval of Vevye 0.1%, for the treatment of the signs and symptoms of dry eye disease

    Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the FDA has approved Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease

    Blue test tubes arranged in a line, disappearing into the background
    News
    12/11/24

    FDA approves Eysuvis for short term treatment of dry eye disease.- Kala Pharma

    Journals
    Journal
    01/09/19

    Unmet Needs in Ophthalmology: A European Vision Institute-Consensus Roadmap 2019-2025

    Purpose: To define unmet needs in ophthalmology that can realistically be addressed in the next 5 years (2019-2025) and describe potential avenues for research to address these challenges.

    • Source: Ophthalmic Research
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/07/22

    Reproxalap ophthalmic solution achieves primary endpoints in dry eye disease chamber crossover clinical trial.-Aldeyra Therapeutics.

    Aldeyra Therapeutics, Inc. announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease.

    See more